Company intelligence / Profile preview

Ningbo Rongan Biological Pharmaceutical Co., Ltd.

Ningbo, Zhejiang Province, Chinaaimbio.com ↗

Ownership: Private
Development stage: Other

Overview

Ningbo Rongan Biological Pharmaceutical specializes in manufacturing freeze-dried human rabies vaccines using Vero cell technology. Its flagship product has been approved since September 2007 in China. The company holds a leading market position as one of the largest suppliers globally and within China. It continues to innovate with next-generation serum-free and mRNA-based rabies vaccines currently advancing through late-stage clinical trials under its parent AIM Vaccine Group. The group also develops a broad range of prophylactic human vaccines targeting major infectious diseases.

Therapeutic areas: Infectious Diseases
Modalities: Prophylactic vaccinesmRNA vaccines
Industry: Biotech

Beyond the preview

Go deeper on Ningbo Rongan Biological Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ningbo Rongan Biological Pharmaceutical Co., Ltd..